Assessment of Safety and Efficacy of SGLT2is Among LN Patients

Inclusion Criteria: * Patients aged more than 18 year. * Patients with confirmed SLE according to EULAR/ACR classification criteria. * Patients with LN ( persistent proteinuria \> 2 gm per day or greater than 3+ by dipstick, and/or cellular casts including red cell, hemoglobin, granular, tubular or mixed \& "active urinary sediment" (\>5 RBC/hpf, \>5 WBC/hpf in the absence of infection, or cellular casts limited to RBC or WBC casts ) * Patient with e GFR \> 25 ml/min/1.73m2 by CKD-EPI equation. Exclusion Criteria: * Patients with an allergy or intolerance to Dapagliflozin or any prior SGLT2i exposure within 1 month before screening. * Medical history of chronic disease (Severe respiratory distress, gastrointestinal tract lesions \& chronic liver disease) * Patients with recurrent genitourinary infections. * Patient with proteinuria \< 2gm. * Patient who show response to immune therapy in proteinuria reduction \> 50%. * Patient with Lupus in induction phase. * Patient on steroids \> 30 mg daily dose. * Patients with diabetes mellitus. * Patients with severe infection requiring antibiotics within 1 month before screening. * Patients with malignant diseases. * Pregnant or breast-feeding women. * Patients with eGFR \< 25 ml/min/1.73m2 or undergoing dialysis therapy